88537-45-5

Basic information

• Product Name: Benzenebutanol, 4-methoxy-, 4-methylbenzenesulfonate
• CAS NO: 88537-45-5
• Molecular Formula: C18H22O4S
• Molecular Weight: 334.436
• Mol File: 88537-45-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzenebutanol, 4-methoxy-, 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanol, 4-methoxy-, 4-methylbenzenesulfonate(88537-45-5)
• EPA Substance Registry System: Benzenebutanol, 4-methoxy-, 4-methylbenzenesulfonate(88537-45-5)

Safety Data

• Hazardous Substances Data: 88537-45-5(Hazardous Substances Data)

Upstream product

• 52244-70-9 4-(4-methoxyphenyl)butan-1-ol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 18272-84-9 4-n-butylanisole 
• 20574-98-5 4-(p-methoxyphenyl)but-1-ene 
• 391202-16-7 1-(4-(4-methoxyphenyl)butyl)-1H-1,2,3-triazole 
• 366016-82-2 4-[4-(1H-1,2,3-triazole-1-yl)butyl]phenol 
• 72457-26-2 4-(4-Methoxyphenyl)butylamine 
• 7508-04-5 5-(4-methoxyphenyl)pentanoic acid 
• 583825-27-8 1-(4-azidobutyl)-4-methoxybezene 
• 74185-15-2 1,7-bis(4-methoxyphenyl)heptan-3-ol 
• 88537-41-1 1,7-bis(3-iodo-4-methoxyphenyl)heptan-3-yl acetate 
• 88537-48-8 3-(3-iodo-4-methoxyphenyl)propyl 4-(3-iodo-4-methoxyphenyl)butyl sulphone 
• 88537-40-0 Acetic acid 5-(4-methoxy-phenyl)-1-[2-(4-methoxy-phenyl)-ethyl]-pentyl ester 
• 88537-47-7 3-(4-methoxyphenyl)propyl 4-(4-methoxyphenyl)butyl sulphone 
• 88537-46-6 3-(4-methoxyphenyl)propyl 4-(4-methoxyphenyl)butyl sulphide 
• 705266-31-5 N,N-bis-(4-(4-methoxyphenyl)butyl)-p-toluenesulfonamide 

Relevant articles and documents

Synthesis of 11C-labelled bis(phenylalkyl)amines and their in vitro and in vivo binding properties in rodent and monkey brains

Two new 11C-labelled ligands, N-(3-(4-hydroxyphenyl)propyl)-3- (4-methoxyphenyl)propylamine ([11C]2) and N-(3-(4-hydroxyphenyl) butyl)-3-(4-methoxyphenyl)butylamine ([11C]3) were designed based on bis(phenylalkyl)-amines (1) which have been reported as polyamine site antagonists with high-selectivity for NR1A/2B NMDA receptors, and radiolabelling of the corresponding phenol precursors with [11C]methyl iodide was readily accomplished. The in vitro inhibition experiments using rat brain slices showed that [11C]2 and [11C]3 share the binding sites with spermine and/or ifenprodil but not with CP-101,606, a highly potent NR2B-selective NMDA antagonist, and that divalent cations such as Zn 2+ produced significant inhibition of both [11C]2 and [11C]3 bindings. Intravenous injection of [11C]3 in mice showed almost homogenous distribution throughout the brain. Attempts to block the tracer uptake of [11C]3 by pre-injection with the unlabelled 3 or spermine in rats were unsuccessful, but a small decrease in the cerebral uptake of [11C]3 by co-treatment with the unlabelled 3 was observed in a monkey PET study. The present findings indicate that none of these 11C-labelled analogues have potential for PET study of binding sites on the N-methly-D-aspartate (NMDA) receptors.

SODIUM CHANNEL BLOCKERS

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

Sodium channel blockers

The present invention relates to sodium channel blockers. The present invention also relates to a variety of methods of treatment using the sodium channel blockers.